
REVIVA PHARMACEUTICALS HOLDINGS, INC.
70
Recent developments include a $10 million public offering completed in March 2026 to fund clinical trials, including a schizophrenia trial, which affected the share price. The company maintains strong liquidity and reported a net loss for Q3 2026.
- Reviva Pharmaceuticals completed a $10 million public offering in March 2026, providing cash runway through Q1 2027 [N3].
- The company proposed an offering to fund a schizophrenia trial, which led to a 41% decline in share price in March 2026 [N3].
- The company reported a net loss of approximately $2.3 million for Q3 2026 with basic EPS of -$0.17 [S2].
- Liquidity ratios as of September 30, 2026, were strong with a current ratio of 3.39 and cash ratio of 3.19 [S2].
- No material changes to risk factors were disclosed in the latest 10-Q filing [S2].
REVIVA PHARMACEUTICALS HOLDINGS, INC. is a pharmaceutical company engaged in clinical development activities, including trials for schizophrenia. The company maintains strong liquidity with over $17 million in cash and equivalents as of Q3 2026. It has recently raised capital through a $10 million public offering to support its clinical programs. The company reported a net loss for the quarter ended September 30, 2026, consistent with ongoing development-stage expenses. Risk factors remain consistent with prior disclosures.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. REVIVA PHARMACEUTICALS HOLDINGS, INC. reported a net loss of $2.3 million for Q3 2026 with strong liquidity ratios (current ratio 3.39, cash ratio 3.19) as of September 30, 2026. The company completed a $10 million public offering in March 2026 to fund clinical trials, including a schizophrenia trial, which impacted its share price. No material changes to risk factors were disclosed in the latest filings [S2][N3].
The company has secured capital through a recent public offering, providing liquidity to advance clinical trials, including for schizophrenia. Continued progress in clinical development and potential regulatory approvals could enhance business visibility and value. The reiterated buy recommendation by HC Wainwright & Co. suggests some analyst confidence in the company's prospects [N3].
The company reported a net loss and negative earnings per share for Q3 2026, reflecting ongoing expenses without current revenue. The share price experienced significant decline following the announcement of a proposed offering to fund clinical trials, indicating market sensitivity to dilution and execution risks. Clinical trial outcomes and regulatory approvals remain uncertain, posing risks to business continuity and valuation.
The company operates in the pharmaceutical development sector, which typically involves high barriers to entry due to regulatory requirements, clinical trial complexities, and intellectual property protections. However, specific competitive advantages or proprietary technologies for REVIVA PHARMACEUTICALS HOLDINGS, INC. are not detailed in the available disclosures.
• Clinical Trial Risk: The company is funding clinical trials, including for schizophrenia, which carry inherent risks of failure or delays that could materially affect business prospects.
• Financial Risk: Despite recent capital raises, the company reported a net loss and depends on continued financing to support operations, which may dilute existing shareholders.
• Market Risk: The share price has shown volatility related to financing announcements, reflecting investor concerns about dilution and execution risks.
• Regulatory Risk: Pharmaceutical development is subject to stringent regulatory approvals, and failure to obtain necessary approvals could adversely impact the company.
Business trends: The company is focused on advancing clinical trials, particularly in schizophrenia, supported by recent capital raises.
Execution milestones: Completion of a $10 million public offering and maintenance of strong liquidity ratios as of Q3 2026.
Key risks: Clinical trial outcomes, regulatory approvals, financial sustainability, and market sensitivity to dilution and execution risks.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- REVIVA PHARMACEUTICALS HOLDINGS, INC. is a pharmaceutical company as indicated by its name and context.
- The company filed a 10-Q quarterly report for the period ending September 30, 2026, filed on November 13, 2026 [S2].
- As of September 30, 2026, the company had cash and cash equivalents of $17,458,418 USD [S2].
- Current assets as of September 30, 2026 were $18,557,325 USD, and current liabilities were $5,477,964 USD, resulting in a current ratio of 3.39 and a cash ratio of 3.19, indicating strong liquidity [S2].
- The company reported a net loss of $2,298,905 USD for the quarter ended September 30, 2026, with basic earnings per share of -$0.17 [S2].
- There were no material changes to risk factors disclosed in the latest 10-Q compared to prior filings [S2].
- Recent news indicates the company completed a $10 million public offering in March 2026, providing a cash runway through Q1 2027 [N3].
- The company proposed an offering to fund a schizophrenia trial, which caused a 41% share price decline in March 2026 [N3].
- The company is engaged in clinical trials related to schizophrenia, as implied by the offering to fund such a trial [N3].
- The company has been covered by HC Wainwright & Co. with a reiterated buy recommendation as of December 2025 [N3].
Generated 2026-11-15
- S1 | 2026-03-27 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-15 | www.nasdaq.com | Nvidia's Ousted CEO Said a 1-Gigawatt Data Center Delay Costs $10 Billion a Quarter. Here's Why That Matters for Power Stocks. | https://www.nasdaq.com/articles/nvidias-ousted-ceo-said-1-gigawatt-data-center-delay-costs-10-billion-quarter-heres-why
- N2 | 2026-11-14 | www.nasdaq.com | Elon Musk's Tesla and SpaceX Lost More Than $420 Billion in Combined Market Value in Two Days After Democrats Swept the Midterms, With Investors Fearing New Congressional Probes. Here's Why That Political Risk Matters for Shareholders | https://www.nasdaq.com/articles/elon-musks-tesla-and-spacex-lost-more-420-billion-combined-market-value-two-days-after
- N3 | 2026-08-13 | www.nasdaq.com | MTR H1 Profit Rises; Revenue Down 4.1% | https://www.nasdaq.com/articles/mtr-h1-profit-rises-revenue-down-41
- N4 | 2026-08-13 | www.nasdaq.com | Aceso Life Science Reports FY2026 Profit On Strategic Realignment | https://www.nasdaq.com/articles/aceso-life-science-reports-fy2026-profit-strategic-realignment
- N5 | 2026-08-13 | www.nasdaq.com | Jensen Huang Just Signed 7 Japanese Industrial Giants Into Nvidia's Physical AI Coalition. Here's Why $1 Trillion in Confirmed Demand Should Matter to Investors. | https://www.nasdaq.com/articles/jensen-huang-just-signed-7-japanese-industrial-giants-nvidias-physical-ai-coalition-heres
- N6 | 2026-08-13 | www.nasdaq.com | The Next Big AI Market Bottleneck Is Here: 8 Stocks to Play the Boom in Optics | https://www.nasdaq.com/articles/next-big-ai-market-bottleneck-here-8-stocks-play-boom-optics
- N7 | 2026-08-13 | www.nasdaq.com | Treasury Wine Swings To Full-year Loss, Revenue Declines; Suspends Dividend | https://www.nasdaq.com/articles/treasury-wine-swings-full-year-loss-revenue-declines-suspends-dividend
- N8 | 2026-08-13 | www.nasdaq.com | Stocks Close Higher on Favorable CPI Report and Positive AI News | https://www.nasdaq.com/articles/stocks-close-higher-favorable-cpi-report-and-positive-ai-news
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


